epiClinicalA fictional CRO

epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.

EPI-118, Phase II. In start-up

Treatment-resistant major depressive disorder

FBK-118 against placebo in treatment-resistant major depressive disorder. Sponsor: Fabrikam Neuroscience (fictional), CNS and psychiatry.

Which sites are ahead, on target or behind their expectation, where each loses its patients, and what might help.

Sites at a glance

Data to September 30th 2026. Sponsor: Fabrikam Neuroscience (fictional). Study-level KPIs and QTLs have their own tabs: KPIs and QTLs.

Patients randomised

0 of 243

0% of the target

Sites open

0 of 135

135 still to open

Patients screened

0

No change: +0 in the last three months

Sites behind their expectation

None judged

Every site is too early to judge: fewer than two patients expected so far

Agreed, of patients approached

0%

55% in published cancer trials

Randomised, of patients screened

0%

The plan assumed 43%

Are enough patients being screened?

No patient has been screened yet; the plan expects the first screens once sites open.

Screening has barely started

Patients screenedCumulative, against the screens the plan implies: its expected randomisations divided by the 43% it expects to pass screening

Show data
Patients screened: planned and actual, by month
MonthPlannedActual
May 202600
Aug 202600
Oct 202600

Sources: epiClinical synthetic screening logs; screen failure by therapeutic area from the planner parameters (D23)

How each kind of site is doing

Each site is compared with what it was expected to recruit in its months open, given its type, track record, country and the protocol. Below 75% of that is behind; above 125% is ahead.

No site has been expected to recruit two patients yet, so none can be judged. The study is still in start-up.

Sites behind, and what might help

No site is behind its expectation.

Every site

Show all 135 sites
SiteProfileMonths openExpectedRandomisedApproachedScreenedPassed screeningStanding
118-US-01, DenverSite new to research0.00.0000–Too early
118-US-02, BaltimoreDedicated research centre0.00.0000–Too early
118-US-03, NashvilleCommunity specialist practice0.00.0000–Too early
118-US-04, PhiladelphiaDedicated research centre0.00.0000–Too early
118-US-05, MinneapolisRegional teaching hospital0.00.0000–Too early
118-US-06, MiamiRegional teaching hospital0.00.0000–Too early
118-US-07, PittsburghSite new to research0.00.0000–Too early
118-US-08, Los AngelesSite new to research0.00.0000–Too early
118-US-09, CharlotteDedicated research centre0.00.0000–Too early
118-US-10, BostonCommunity specialist practice0.00.0000–Too early
118-US-11, AtlantaSite new to research0.00.0000–Too early
118-US-12, ChicagoAcademic medical centre0.00.0000–Too early
118-US-13, HoustonSite new to research0.00.0000–Too early
118-US-14, San DiegoSite new to research0.00.0000–Too early
118-US-15, DallasDedicated research centre0.00.0000–Too early
118-US-16, Salt Lake CitySite new to research0.00.0000–Too early
118-US-17, ClevelandDedicated research centre0.00.0000–Too early
118-US-18, New YorkSite new to research0.00.0000–Too early
118-US-19, PhoenixRegional teaching hospital0.00.0000–Too early
118-US-20, SeattleDedicated research centre0.00.0000–Too early
118-US-21, DenverSite new to research0.00.0000–Too early
118-US-22, BaltimoreSite new to research0.00.0000–Too early
118-US-23, NashvilleCommunity hospital0.00.0000–Too early
118-US-24, PhiladelphiaSite new to research0.00.0000–Too early
118-US-25, MinneapolisSite new to research0.00.0000–Too early
118-US-26, MiamiSite new to research0.00.0000–Too early
118-US-27, PittsburghDedicated research centre0.00.0000–Too early
118-US-28, Los AngelesAcademic medical centre0.00.0000–Too early
118-US-29, CharlotteSite new to research0.00.0000–Too early
118-US-30, BostonCommunity hospital0.00.0000–Too early
118-US-31, AtlantaCommunity specialist practice0.00.0000–Too early
118-US-32, ChicagoSite new to research0.00.0000–Too early
118-US-33, HoustonDedicated research centre0.00.0000–Too early
118-US-34, San DiegoCommunity hospital0.00.0000–Too early
118-US-35, DallasDedicated research centre0.00.0000–Too early
118-US-36, Salt Lake CitySite new to research0.00.0000–Too early
118-US-37, ClevelandSite new to research0.00.0000–Too early
118-US-38, New YorkSite new to research0.00.0000–Too early
118-US-39, PhoenixDedicated research centre0.00.0000–Too early
118-US-40, SeattleCommunity specialist practice0.00.0000–Too early
118-US-41, DenverSite new to research0.00.0000–Too early
118-US-42, BaltimoreRegional teaching hospital0.00.0000–Too early
118-US-43, NashvilleSite new to research0.00.0000–Too early
118-US-44, PhiladelphiaSite new to research0.00.0000–Too early
118-US-45, MinneapolisRegional teaching hospital0.00.0000–Too early
118-US-46, MiamiDedicated research centre0.00.0000–Too early
118-US-47, PittsburghCommunity hospital0.00.0000–Too early
118-US-48, Los AngelesSite new to research0.00.0000–Too early
118-US-49, CharlotteDedicated research centre0.00.0000–Too early
118-US-50, BostonSite new to research0.00.0000–Too early
118-US-51, AtlantaSite new to research0.00.0000–Too early
118-US-52, ChicagoSite new to research0.00.0000–Too early
118-US-53, HoustonCommunity specialist practice0.00.0000–Too early
118-US-54, San DiegoSite new to research0.00.0000–Too early
118-US-55, DallasRegional teaching hospital0.00.0000–Too early
118-US-56, Salt Lake CitySite new to research0.00.0000–Too early
118-US-57, ClevelandDedicated research centre0.00.0000–Too early
118-US-58, New YorkCommunity specialist practice0.00.0000–Too early
118-US-59, PhoenixCommunity specialist practice0.00.0000–Too early
118-US-60, SeattleSite new to research0.00.0000–Too early
118-UK-01, CambridgeAcademic medical centre0.00.0000–Too early
118-UK-02, NewcastleRegional teaching hospital0.00.0000–Too early
118-UK-03, NottinghamCommunity hospital0.00.0000–Too early
118-UK-04, OxfordCommunity hospital0.00.0000–Too early
118-UK-05, LeedsSite new to research0.00.0000–Too early
118-UK-06, LiverpoolRegional teaching hospital0.00.0000–Too early
118-UK-07, SheffieldCommunity hospital0.00.0000–Too early
118-UK-08, ManchesterAcademic medical centre0.00.0000–Too early
118-UK-09, BirminghamAcademic medical centre0.00.0000–Too early
118-UK-10, SouthamptonRegional teaching hospital0.00.0000–Too early
118-UK-11, CardiffRegional teaching hospital0.00.0000–Too early
118-UK-12, GlasgowSite new to research0.00.0000–Too early
118-UK-13, EdinburghDedicated research centre0.00.0000–Too early
118-UK-14, LondonCommunity hospital0.00.0000–Too early
118-UK-15, BristolRegional teaching hospital0.00.0000–Too early
118-UK-16, CambridgeSite new to research0.00.0000–Too early
118-UK-17, NewcastleSite new to research0.00.0000–Too early
118-UK-18, NottinghamSite new to research0.00.0000–Too early
118-UK-19, OxfordAcademic medical centre0.00.0000–Too early
118-UK-20, LeedsRegional teaching hospital0.00.0000–Too early
118-UK-21, LiverpoolSite new to research0.00.0000–Too early
118-UK-22, SheffieldCommunity hospital0.00.0000–Too early
118-UK-23, ManchesterAcademic medical centre0.00.0000–Too early
118-UK-24, BirminghamSite new to research0.00.0000–Too early
118-UK-25, SouthamptonRegional teaching hospital0.00.0000–Too early
118-ES-01, GranadaRegional teaching hospital0.00.0000–Too early
118-ES-02, MadridSite new to research0.00.0000–Too early
118-ES-03, SalamancaCommunity specialist practice0.00.0000–Too early
118-ES-04, OviedoSite new to research0.00.0000–Too early
118-ES-05, PamplonaCommunity specialist practice0.00.0000–Too early
118-ES-06, SevilleCommunity hospital0.00.0000–Too early
118-ES-07, BarcelonaSite new to research0.00.0000–Too early
118-ES-08, ZaragozaSite new to research0.00.0000–Too early
118-ES-09, ValenciaAcademic medical centre0.00.0000–Too early
118-ES-10, MálagaSite new to research0.00.0000–Too early
118-ES-11, BilbaoSite new to research0.00.0000–Too early
118-ES-12, AlicanteSite new to research0.00.0000–Too early
118-ES-13, MurciaRegional teaching hospital0.00.0000–Too early
118-ES-14, Santiago de CompostelaRegional teaching hospital0.00.0000–Too early
118-ES-15, CórdobaRegional teaching hospital0.00.0000–Too early
118-ES-16, GranadaSite new to research0.00.0000–Too early
118-ES-17, MadridSite new to research0.00.0000–Too early
118-ES-18, SalamancaCommunity specialist practice0.00.0000–Too early
118-ES-19, OviedoSite new to research0.00.0000–Too early
118-ES-20, PamplonaDedicated research centre0.00.0000–Too early
118-ES-21, SevilleAcademic medical centre0.00.0000–Too early
118-ES-22, BarcelonaSite new to research0.00.0000–Too early
118-ES-23, ZaragozaSite new to research0.00.0000–Too early
118-ES-24, ValenciaSite new to research0.00.0000–Too early
118-ES-25, MálagaDedicated research centre0.00.0000–Too early
118-PL-01, OlsztynSite new to research0.00.0000–Too early
118-PL-02, BydgoszczDedicated research centre0.00.0000–Too early
118-PL-03, LublinSite new to research0.00.0000–Too early
118-PL-04, BiałystokDedicated research centre0.00.0000–Too early
118-PL-05, PoznańAcademic medical centre0.00.0000–Too early
118-PL-06, ŁódźCommunity hospital0.00.0000–Too early
118-PL-07, WrocławSite new to research0.00.0000–Too early
118-PL-08, ZamośćRegional teaching hospital0.00.0000–Too early
118-PL-09, GdańskDedicated research centre0.00.0000–Too early
118-PL-10, RzeszówSite new to research0.00.0000–Too early
118-PL-11, WarsawSite new to research0.00.0000–Too early
118-PL-12, SzczecinDedicated research centre0.00.0000–Too early
118-PL-13, KatowiceSite new to research0.00.0000–Too early
118-PL-14, KrakówDedicated research centre0.00.0000–Too early
118-PL-15, OlsztynSite new to research0.00.0000–Too early
118-PL-16, BydgoszczSite new to research0.00.0000–Too early
118-PL-17, LublinSite new to research0.00.0000–Too early
118-PL-18, BiałystokDedicated research centre0.00.0000–Too early
118-PL-19, PoznańDedicated research centre0.00.0000–Too early
118-PL-20, ŁódźSite new to research0.00.0000–Too early
118-PL-21, WrocławDedicated research centre0.00.0000–Too early
118-PL-22, ZamośćSite new to research0.00.0000–Too early
118-PL-23, GdańskAcademic medical centre0.00.0000–Too early
118-PL-24, RzeszówSite new to research0.00.0000–Too early
118-PL-25, WarsawSite new to research0.00.0000–Too early

Rules behind this page

  • A site that has recruited below this share of its expected count is behind: 75%. epiClinical assumption, between the enrolment flag (0.8) and the point NCI trials rarely recovered from (0.6); about half of sites fall short of plan in practice (11% enrol nobody, 37% under-enrol; Tufts, register S-01).
  • A site that has recruited above this share of its expected count is ahead: 125%. epiClinical assumption, set symmetrically to the behind line on a ratio scale (1 ÷ 0.8).
  • Patients a site must have been expected to recruit before it is judged: 2. epiClinical assumption: below this, a site's count says more about chance than about the site.
  • Patients offered a trial who agree to take part: 55%. 55.0% of patients offered a cancer treatment trial agreed, across 35 studies (Unger 2021, JNCI, https://doi.org/10.1093/jnci/djaa155).
  • Patients needed at a funnel stage before a site's rate there is compared with the study's: 8. epiClinical assumption: with fewer, a single patient moves the rate by more than ten points.
  • A site's rate at a funnel stage is out of line when so poor a rate would happen by chance less often than this: 0.1. epiClinical assumption: a loose screen, because it prompts a look at the screening log rather than a judgement.
  • Patients fail screening: Screen failure is high and varies widely by therapeutic area (register PM-05); restrictive criteria are the commonest design barrier (PB-02, PD-01).
  • Patients wait too long for scans: epiClinical assumption from CRA practice; procedures per protocol rose 40.6% since 2010, which weighs on sites without services on site (register S-24).
  • Too little coordinator time: Coordinator turnover of 10 to 37% a year, rising to 35 to 61% in 2022; 45% of sites say capacity limits new studies (register S-09, S-11).
  • Competing trials take the same patients: Competing trials for the same patients reduce enrolment where the eligible pool is scarce (register EB-02, S-21).
  • Too few patients referred: Research-focused sites recruit about 41% better, but depend on referral routes (register S-07); referral networks lack outcome evidence (action A14).
  • Patients decline because of the journey: Procedural and visit burden lowers enrolment and retention (register PD-03); decentralised elements help mainly where travel is the barrier (PD-20).